Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Moderna, GSK
GSK sues Moderna over mRNA vaccine technology
GlaxoSmithKline is suing Moderna for allegedly using technology patented by GSK in its COVID-19 vaccine. Why it matters: It's the latest in a series of legal fights over who owns the intellectual property behind mRNA technology and whether some companies are entitled to royalties on future sales.
GlaxoSmithKline sues Moderna for US patent infringement over COVID vaccines
GlaxoSmithKline sued Moderna in Delaware federal court on Tuesday for allegedly violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax. The lawsuit said Moderna's lipid nanoparticles for transporting mRNA into the human body infringe several GSK patents covering similar innovations.
Patent Wars: GSK Takes on Moderna Over mRNA Innovations
GlaxoSmithKline has filed lawsuits against Moderna in a Delaware federal court, alleging infringement of patents related to mRNA technology in Moderna's COVID-19 vaccine Spikevax and RSV shot mResvia.
GSK sues Moderna over US patent violation of Spikevax COVID-19 vaccine
A Moderna spokesperson said the company was aware of the new litigation and would defend itself against the claims
Northwestern sues Moderna for patent infringement over COVID-19 vaccines
Moderna was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused the company of misusing the school's innovations to develop its blockbuster COVID-19 vaccine Spikevax.
GSK Sues Moderna Over mRNA Vaccine Patents
GlaxoSmithKline (GSK) has filed a patent infringement lawsuit against Moderna in Delaware, accusing the company of using its patented mRNA technology in their Spikevax COVID-19 vaccine without permission.
British drugmaker sues Moderna for patent infringement related to mRNA vaccines
A British drugmaker, GlaxoSmithKline (GSK), has sued American pharmaceutical company Moderna claiming it violated patent rights in its mRNA technology used to develop its COVID-19 and RSV vaccines.
FiercePharma
1d
With Gilead coming fast, GSK bolsters case for long-acting HIV PrEP drug Apretude
With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...
8d
GlaxoSmithKline Settles Most Zantac Lawsuits for $2.2B
The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.
manilastandard
3d
GSK gets FDA approval for meningococcal vaccine
Pharmaceutical firm GlaxoSmithKline (GSK) announced Tuesday it received approval from the Food and Drug Administration (FDA) ...
7d
on MSN
GSK jumps 6% after $2.2B Zantac settlement: why analysts see more upside
GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 ...
2d
GSK sues Moderna for US patent infringement over COVID, RSV vaccines
British drugmaker GlaxoSmithKline sued Moderna in U.S. federal court in Delaware on Tuesday, accusing its American rival of ...
17h
GSK rises Thursday, still underperforms market
GSK PLC GSK shares inched up 0.03% to £14.97 Thursday, on what proved to be an all-around favorable trading session for the ...
1d
GSK Seeks FDA Approval For Oral Antibiotic For Urinary Tract Infections, Probably First In New Class In Over 20 Years
GSK's gepotidacin, an oral antibiotic for uUTIs, could be the first in over 20 years. The FDA granted Priority Review with a ...
FierceBiotech
1d
Wave hails first for human RNA editing with GSK-partnered prospect, sending stock skyward
Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
COVID-19
Moderna
Feedback